Detalles de la búsqueda
1.
Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial.
Br J Cancer
; 129(4): 706-720, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37420000
2.
Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning.
Gut
; 70(3): 544-554, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32690604
3.
Adding new experimental arms to randomised clinical trials: Impact on error rates.
Clin Trials
; 17(3): 273-284, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32063029
4.
Choosing the right strategy based on individualized treatment effect predictions: combination versus sequential chemotherapy in patients with metastatic colorectal cancer.
Acta Oncol
; 58(3): 326-333, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30657353
5.
Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab.
J Med Genet
; 54(8): 567-571, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28283541
6.
Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer.
Hum Mol Genet
; 22(4): 825-31, 2013 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23184150
7.
Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.
Lancet Oncol
; 15(6): 631-9, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24703531
8.
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials.
Eur J Cancer
; 190: 112945, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37441940
9.
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Lancet
; 377(9783): 2103-14, 2011 Jun 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-21641636
10.
The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS).
Value Health
; 15(1): 22-31, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22264968
11.
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Lancet Oncol
; 12(7): 642-53, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21641867
12.
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.
J Clin Oncol
; 40(16): 1772-1782, 2022 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35213214
13.
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.
Contemp Clin Trials
; 108: 106482, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34538402
14.
RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting.
Contemp Clin Trials
; 108: 106481, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34538401
15.
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.
J Clin Oncol
; 38(34): 4064-4075, 2020 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33052759
16.
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Lancet
; 370(9582): 143-152, 2007 Jul 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-17630037
17.
Reply to U. Capitanio et al.
J Clin Oncol
; 41(3): 704-706, 2023 01 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36166721
18.
Methods for delivering the UK's multi-centre prison-based naloxone-on-release pilot randomised trial (N-ALIVE): Europe's largest prison-based randomised controlled trial.
Drug Alcohol Rev
; 37(4): 487-498, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28940805
19.
Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.
Eur J Cancer
; 102: 31-39, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-30114658
20.
What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial.
Kidney Cancer
; 2(2): 123-131, 2018 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30740581